Alterations of brain eicosanoid synthetic pathway in multiple sclerosis and in animal models of demyelination: Role of cyclooxygenase-2

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 5, 2013, Pages 273-278

  Palumbo, Sara ^a   Bosetti, Francesca ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Arachidonic acid; Cuprizone; Cyclooxigenases; EAE; Multiple sclerosis; NSAID; Theiler's virus

Indexed keywords

ACETYLSALICYLIC ACID; BETA INTERFERON; CELECOXIB; CORTICOSTEROID; CUPRIZONE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; ICOSANOID; INDOMETACIN; INTERLEUKIN 10; LIPOXYGENASE; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

ALLERGIC ENCEPHALOMYELITIS; ARACHIDONIC ACID METABOLISM; ASTROCYTE; CYTOKINE PRODUCTION; DEMYELINATION; FLU LIKE SYNDROME; HUMAN; ICOSANOID METABOLISM; MACROPHAGE; MICROGLIA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; REMISSION; REVIEW;

ANIMALIA; THEILER'S ENCEPHALOMYELITIS VIRUS;

ARACHIDONIC ACID; CUPRIZONE; CYCLOOXIGENASES; EAE; MULTIPLE SCLEROSIS; NSAID; THEILER'S VIRUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; ASTROCYTES; BRAIN; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; EICOSANOIDS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIPOXYGENASE; MICROGLIA; MULTIPLE SCLEROSIS;

EID: 84886948548     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.08.008     Document Type: Article

References (57)

1. Wingerchuk D.M. Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt. Sinai J. Med. 2011, 78(2):221-230.
2. Noseworthy J.H., et al. Multiple sclerosis. N. Engl. J. Med. 2000, 343(13):938-952.
3. Aid S., et al. Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation. Neurosci. Lett. 2010, 478(3):113-118.
4. Lucchinetti C.F., et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996, 6(3):259-274.
5. Menge T., et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008, 68(17):2445-2468.
6. Rice G.P. Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects. BioDrugs 1999, 12(4):267-277.
7. Neu I., et al. Leukotrienes in the cerebrospinal fluid of multiple sclerosis patients. Acta. Neurol. Scand. 1992, 86(6):586-587.
8. Neu I.S., et al. Leukotrienes in patients with clinically active multiple sclerosis. Acta. Neurol. Scand. 2002, 105(1):63-66.
9. Dore-Duffy P., et al. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 1986, 36(12):1587-1590.
10. Dore-Duffy P., Ho S.Y., Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 1991, 41(2):322-324.
11. Greco A., et al. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999, 53(8):1876-1879.
12. Rosnowska M., et al. Prostaglandins E2 and F2 alpha in the cerebrospinal fluid in patients with multiple sclerosis. Acta. Med. Pol. 1981, 22(1):97-103.
13. Bolton C., Turner A.M., Turk J.L. Prostaglandin levels in cerebrospinal fluid from multiple sclerosis patients in remission and relapse. J. Neuroimmunol. 1984, 6(3):151-159.
14. Mattsson N., et al. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J. Intern. Med. 2009, 265(4):459-464.
15. Rose J.W., et al. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J. Neuroimmunol. 2004, 149(1-2):40-49.
16. Carlson N.G., et al. Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. J. Neuroinflammation 2010, 7:25.
17. Carlson N.G., et al. The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J. Neuroimmunol. 2006, 174(1-2):21-31.
18. Skarke C., et al. Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics 2007, 8(12):1643-1660.
19. Whitney L.W., et al. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. 2001, 121(1-2):40-48.
20. Arthur A.T., et al. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med. Genet. 2008, 9:17.
21. Munschauer F.E., Kinkel R.P. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin. Ther. 1997, 19(5):883-893.
22. Mora J.S., Kao K.P., Munsat T.L. Indomethacin reduces the side effects of intrathecal interferon. N. Engl. J. Med. 1984, 310(2):126-127.
23. Reess J., et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy. Mult. Scler. 2002, 8(1):15-18.
24. Rio J., et al. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology 2004, 63(3):525-528.
25. Brandes D.W., et al. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. Curr. Med. Res. Opin. 2007, 23(7):1667-1672.
26. Leuschen M.P., Filipi M., Healey K. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult. Scler. 2004, 10(6):636-642.
27. Wingerchuk D.M., et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005, 64(7):1267-1269.
28. Kipp M., et al. The cuprizone animal model: new insights into an old story. Acta. Neuropathol. 2009, 118(6):723-736.
29. Stohlman S.A., Hinton D.R. Viral induced demyelination. Brain. Pathol. 2001, 11(1):92-106.
30. Lucchinetti C., Bruck W., Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr. Opin. Neurol. 2001, 14(3):259-269.
31. Mix E., Meyer-Rienecker H., Zettl U.K. Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J. Neurol. 2008, 255(Suppl. 6):7-14.
32. Brown D.A., Sawchenko P.E. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 2007, 502(2):236-260.
33. Mandolesi G., et al. Cognitive deficits in experimental autoimmune encephalomyelitis: neuroinflammation and synaptic degeneration. Neurol. Sci. 2010, 31(Suppl. 2):S255-S259.
34. Constantinescu C.S., et al. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 2011, 164(4):1079-1106.
35. Venturini G. Enzymic activities and sodium, potassium and copper concentrations in mouse brain and liver after cuprizone treatment in vivo. J. Neurochem. 1973, 21(5):1147-1151.
36. Komoly S., et al. Decrease in oligodendrocyte carbonic anhydrase activity preceding myelin degeneration in cuprizone induced demyelination. J. Neurol. Sci. 1987, 79(1-2):141-148.
37. Koutsoudaki P.N., et al. Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci. Lett. 2009, 451(1):83-88.
38. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11(1):107-116.
39. Liu L., et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13(3):319-326.
40. Lindner M., et al. Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol. Appl. Neurobiol. 2008, 34(1):105-114.
41. Lindner M., et al. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci. Lett. 2009, 453(2):120-125.
42. Franco-Pons N., et al. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol. Lett. 2007, 169(3):205-213.
43. Kim B.S., et al. Innate immune response induced by Theiler's murine encephalomyelitis virus infection. Immunol. Res. 2005, 31(1):1-12.
44. Tsunoda I., Fujinami R.S. Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J. Neuroimmune. Pharmacol. 2010, 5(3):355-369.
45. Kihara Y., et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc. Natl. Acad. Sci. USA 2009, 106(51):21807-21812.
46. Esaki Y., et al. Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2010, 107(27):12233-12238.
47. Palumbo S., et al. Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination. Prostaglandins Leukot. Essent. Fatty Acids 2011, 478(3):113-118.
48. Palumbo S., et al. The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination. J. Neurochem. 2011, 121(3):418-427.
49. Yoshikawa K., et al. Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85(1):43-52.
50. Bernstein J.A., et al. MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir. Med. 2010, 105(3):392-401.
51. Rossi A., et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br. J. Pharmacol. 2010, 161(3):555-570.
52. Reder A.T., et al. Eicosenoids modify experimental allergic encephalomyelitis. Am. J. Ther. 1995, 2(9):711-720.
53. Marusic S., et al. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J. Neuroimmunol. 2008, 204(1-2):29-37.
54. Muthian G., et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J. Clin. Immunol. 2006, 26(1):73-85.
55. Ni J., et al. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J. Neuroimmunol. 2007, 186(1-2):94-103.
56. Miyamoto K., et al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006, 129(Pt 8):1984-1992.
57. Pollak Y., et al. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of 'depression due to multiple sclerosis'. Brain Behav. Immun. 2002, 16(5):533-543.